The most advanced asset in EHL Bio's cell drug pipeline
Quick answer
ADSTEM inj. is EHL Bio's adipose stem cell drug for severe atopic dermatitis. Phase 1 focuses on safety and tolerated dose; phase 2 starts measuring efficacy such as eczema severity scores and itch. A phase 2 signal is not the same as approval for general use.
People often read 'in clinical trials' as 'ready to use'. Each phase answers a different question: phase 1 asks whether it is safe in a small group, phase 2 asks whether it plausibly works and at what dose, and phase 3 confirms the effect in a large controlled population.
Atopic dermatitis trials typically use EASI or SCORAD, scoring the area and severity of the rash alongside patient-reported itch. So read the numbers: how much the score dropped, in how many patients, and how long the effect held — not just before-and-after photos.
For Thai patients the key point is that an investigational drug is not sold as a package. What a hospital actually delivers falls under Korea's framework for using a patient's own cells, which is different from an approved product — ask the physician to state plainly which one you are receiving.
No. Phase 2 estimates effect and dose; general use requires phase 3 and regulatory approval.
Generally no — trials enrol under the site country's protocol. Overseas participation must be discussed case by case.
Last updated: 2026-08-28 · This content is for information only and is not medical advice. Consult a qualified doctor before making treatment decisions.
Back to categoriesRelated topics: Cell drug pipeline